Peptide Comparison
CapromorelinvsCJC-1295 with DAC
An oral ghrelin agonist originally developed by Pfizer that stimulates growth hormone and appetite. FDA-approved for veterinary use (Entyce and Elura) and investigated in human trials for age-related muscle wasting and appetite support.
Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.
At a Glance
Quick
comparison
Dose Range
Capromorelin
3–30 mg
CJC-1295 with DAC
1000–2000 mcg
Frequency
Capromorelin
Once daily
CJC-1295 with DAC
Twice weekly
Administration
Capromorelin
Oral (capsule or tablet)
CJC-1295 with DAC
Subcutaneous injection
Cycle Length
Capromorelin
4-6 weeks
CJC-1295 with DAC
8-12 weeks
Onset Speed
Capromorelin
Moderate (1-2 weeks)
CJC-1295 with DAC
Moderate (1-2 weeks)
Evidence Level
Capromorelin
Moderate human trials (Phase 1-2)
CJC-1295 with DAC
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
GH & IGF-1 Stimulation
Physical Function
Oral Convenience
GH Elevation
Convenience
Recovery Support
Technical Data
Compound
specifications
Capromorelin
Molecular Formula
C28H35N5O4
Molecular Weight
505.6 g/mol
Half-Life
1-2.4 hours in humans
Bioavailability
Good oral bioavailability
CAS Number
193273-66-4
CJC-1295 with DAC
Molecular Formula
C165H269N47O46
Molecular Weight
3647.28 g/mol
Half-Life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS Number
863288-34-0
Protocols
Dosing
tiers
Capromorelin
CJC-1295 with DAC
Applications
Best
suited for
Capromorelin
Age-Related Muscle Wasting
Capromorelin showed significant improvements in physical function — including tandem walk and stair climb — in elderly adults, making it a strong candidate for combating sarcopenia.
Appetite Stimulation
As an FDA-approved veterinary appetite stimulant, capromorelin has extensive real-world evidence for boosting food intake and body weight in mammals.
Growth Hormone Research
One of the best-studied oral ghrelin agonists with human Phase 2 data, offering researchers a well-characterized tool for studying GH/IGF-1 pathways.
CJC-1295 with DAC
Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.
Safety Profile
Side
effects
Capromorelin
Common
- Appetite stimulation
- Fluid retention and weight gain
Uncommon
- Joint and muscle aches
- Fatigue or lethargy
- Peripheral edema (swelling)
Serious
- Hyperglycemia
CJC-1295 with DAC
Common
- Injection site reactions
- Water retention
- Flushing
- Tingling sensation
Uncommon
- Headaches
- Fatigue or lethargy
- Joint discomfort
Serious
- Carpal tunnel symptoms
- Blood glucose elevation
Research Status
Safety
& evidence
Capromorelin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for this use
Safety Overview
Capromorelin was generally well-tolerated in Phase 2 human trials involving nearly 400 elderly participants. Most side effects were mild to moderate. Its FDA-approved veterinary use provides additional long-term safety data in mammalian species.
Contraindications
- xActive cancer or history of cancer (GH may stimulate growth)
- xUncontrolled diabetes or severe metabolic disorders
- xSevere liver or kidney disease
- xPregnancy and lactation
CJC-1295 with DAC
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.
Contraindications
- xActive cancer or history of malignancy
- xPregnancy or breastfeeding
- xPituitary tumors or disorders
- xDiabetic retinopathy
- xUncontrolled diabetes
Decision Guide
Which is
right for you?
Choose Capromorelin if...
- Stimulating growth hormone production in elderly adults
- Supporting appetite and weight gain in wasting conditions
- Improving muscle mass and physical performance
- Anti-aging and longevity optimization
Choose CJC-1295 with DAC if...
- Boosting natural growth hormone production
- Building lean muscle mass
- Improving body composition
- Anti-aging and longevity